Table 2.
Treatment outcomes
| Patient | # Cycles pembro | # Cycles pom | irAE | ΔCD4+* T cells/μL |
ΔCD8+ T cells/μL |
Best response | Next therapy received | Months from pembro initiation to last follow-up | Long-term outcome |
| 1 | 13 | – | – | +116 | +311 | PR | Allogeneic HSCT | 13 | Death |
| 2 | 7 | – | G2 hypothyroidism | +132 | +754 | SD | Trimetinib | 11 | Death |
| 3 | 6 | – | G2 hypothyroidism | −63 | −152 | SD | Lenalidomide +bortezomib | 15 | SD |
| 4 | 15 | – | – | −43 | −37 | PR | R-ICE followed by allogeneic HSCT | 33 | CR |
| 5 | 6 | – | – | +52 | +43 | PR | RIL | 15 | Death |
| 6 | 7 | 12 | G3 Guillain-Barre | −65 | −74 | SD | HD-MTX-Ara-C-Thiotepa | 24 | SD |
| 7 | 22 | 19 | G3 hepatitis | +70 | +517 | CR | Continued on pembro+pom | 21 | CR |
| 8 | 3 | – | – | −305 | −1458 | PD | – | 3 | Death |
| 9 | 4 | 1 | – | – | – | PD | – | 4 | Death |
| 10 | 7 | 7 | – | +94 | +473 | PR | Daratumumab+pom | 9 | PR |
*The change in CD4+ and CD8+ T cells is measured from baseline to the end of treatment.
Ara-C, cytarabine; CR, complete response; G, grade; HD-MTX, high-dose methotrexate; HSCT, hematopoietic stem cell transplant; irAE, immune-related adverse event; PD, progressive disease; pembro, pembrolizumab; pom, pomalidomide; PR, partial response; R-ICE, rituximab, ifosfamide, carboplatin, etoposide; RIL, rituximab, ibrutinib, lenalidomide; SD, stable disease.